Evidence map›Paper›PMID 33185818›Full record

ArticlePharmacological reports : PR2020

Traumatic brain injury in mice induces changes in the expression of the XCL1/XCR1 and XCL1/ITGA9 axes.

Agata Ciechanowska, Katarzyna Popiolek-Barczyk, Katarzyna Ciapała, Katarzyna Pawlik, Marco Oggioni, Domenico Mercurio, Maria-Grazia de Simoni, Joanna Mika

Abstract read
In one paragraph

Article in Pharmacological reports : PR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Mechanisms of XCR1 Membrane Trafficking and Constitutive Endocytosis.Basic & clinical pharmacology & toxicology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. The multifaceted role of XCL1 in health and disease.Protein science : a publication of the Protein Society · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Agata CiechanowskaDepartment of Pain Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Str., 31-343, Kraków, Poland.
Katarzyna Popiolek-BarczykDepartment of Pain Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Str., 31-343, Kraków, Poland.
Katarzyna CiapałaDepartment of Pain Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Str., 31-343, Kraków, Poland.
Katarzyna PawlikDepartment of Pain Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Str., 31-343, Kraków, Poland.
Marco OggioniDepartment of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri, 2, 20156, Milan, Italy.
Domenico MercurioDepartment of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri, 2, 20156, Milan, Italy.
Maria-Grazia de SimoniDepartment of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri, 2, 20156, Milan, Italy.
Joanna MikaDepartment of Pain Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Str., 31-343, Kraków, Poland. joamika@if-pan.krakow.pl.

Funding

ERA-NET-NEURON JTC 2016: LEAP, NEURON9-FP-044Instytut Farmakologii, Polskiej Akademii Nauk statutory fundsMinistero della Salute -Narodowe Centrum Badań i Rozwoju ERA-NET NEURON-Cofund/1/LEAP/15/17
6 · The paper itself

Abstract

backgroundEvery year, millions of people suffer from various forms of traumatic brain injury (TBI), and new approaches with therapeutic potential are required. Although chemokines are known to be involved in brain injury, the importance of X-C motif chemokine ligand 1 (XCL1) and its receptors, X-C motif chemokine receptor 1 (XCR1) and alpha-9 integrin (ITGA9), in the progression of TBI remain unknown.

methodsUsing RT-qPCR/Western blot/ELISA techniques, changes in the mRNA/protein levels of XCL1 and its two receptors, in brain areas at different time points were measured in a mouse model of TBI. Moreover, their cellular origin and possible changes in expression were evaluated in primary glial cell cultures.

resultsStudies revealed the spatiotemporal upregulation of the mRNA expression of XCL1, XCR1 and ITGA9 in all the examined brain areas (cortex, thalamus, and hippocampus) and at most of the evaluated stages after brain injury (24 h; 4, 7 days; 2, 5 weeks), except for ITGA9 in the thalamus. Moreover, changes in XCL1 protein levels occurred in all the studied brain structures; the strongest upregulation was observed 24 h after trauma. Our in vitro experiments proved that primary murine microglial and astroglial cells expressed XCR1 and ITGA9, however they seemed not to be a main source of XCL1.

conclusionsThese findings indicate that the XCL1/XCR1 and XCL1/ITGA9 axes may participate in the development of TBI. The XCL1 can be considered as one of the triggers of secondary injury, therefore XCR1 and ITGA9 may be important targets for pharmacological intervention after traumatic brain injury.

Indexed as

AnimalsAstrocytesBrain Injuries, TraumaticChemokines, CDisease Models, AnimalDisease ProgressionIntegrin alpha ChainsMaleMiceMice, Inbred C57BLMicrogliaReceptors, ChemokineChemokines, Cintegrin alpha9Integrin alpha ChainsReceptors, ChemokineXC chemokine receptor 1, mouseXcl1 protein, mouseAstrogliaChemokineITGA9MicrogliaTBIXCL1XCR1

Identifiers

PMID33185818
PMCPMC7704520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.